

# (12) International Application Status Report

**Received at International Bureau:** 04 March 2010 (04.03.2010)

**Information valid as of:** 06 August 2010 (06.08.2010)

**Report generated on:** 18 July 2019 (18.07.2019)

**(10) Publication number:**

WO2010/095663

**(43) Publication date:**

26 August 2010 (26.08.2010)

**(26) Publication language:**

Japanese (JA)

**(21) Application Number:**

PCT/JP2010/052374

**(22) Filing Date:**

17 February 2010 (17.02.2010)

**(25) Filing language:**

Japanese (JA)

**(31) Priority number(s):**

61/202,321 (US)

**(31) Priority date(s):**

18 February 2009 (18.02.2009)

**(31) Priority status:**

Priority document received (in compliance with PCT Rule 17.1)

**(51) International Patent Classification:**

*C07D 401/14* (2006.01); *A61K 31/454* (2006.01); *A61K 31/506* (2006.01); *A61K 31/519* (2006.01); *A61K 31/5377* (2006.01); *A61K 31/55* (2006.01); *A61P 1/00* (2006.01); *A61P 1/02* (2006.01); *A61P 1/04* (2006.01); *A61P 1/08* (2006.01); *A61P 1/12* (2006.01); *A61P 1/16* (2006.01); *A61P 1/18* (2006.01); *A61P 3/04* (2006.01); *A61P 3/06* (2006.01); *A61P 3/10* (2006.01); *A61P 7/00* (2006.01); *A61P 9/00* (2006.01); *A61P 9/04* (2006.01); *A61P 9/10* (2006.01); *A61P 9/12* (2006.01); *A61P 11/00* (2006.01); *A61P 13/10* (2006.01); *A61P 13/12* (2006.01); *A61P 15/00* (2006.01); *A61P 17/02* (2006.01); *A61P 17/06* (2006.01); *A61P 19/02* (2006.01); *A61P 19/06* (2006.01); *A61P 19/10* (2006.01); *A61P 21/04* (2006.01); *A61P 25/00* (2006.01); *A61P 25/02* (2006.01); *A61P 25/28* (2006.01); *A61P 27/02* (2006.01); *A61P 27/12* (2006.01); *A61P 27/16* (2006.01); *A61P 29/00* (2006.01); *A61P 31/00* (2006.01); *A61P 35/00* (2006.01); *A61P 35/02* (2006.01); *A61P 43/00* (2006.01); *C07D 405/14* (2006.01); *C07D 413/14* (2006.01); *C07D 487/04* (2006.01)

**(71) Applicant(s):**

TAKEDA PHARMACEUTICAL COMPANY LIMITED [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410045 (JP) (for all designated states except US)

RIKIMARU, Kentaro [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP) (for US only)

IMOTO, Hiroshi [JP/US]; #206, 1742 Sand Hill Road, Palo Alto, California 94304 (US) (for US only)

KAMAURA, Masahiro [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP) (for US only)

**(72) Inventor(s):**

RIKIMARU, Kentaro; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP)

IMOTO, Hiroshi; #206, 1742 Sand Hill Road, Palo Alto, California 94304 (US)

KAMAURA, Masahiro; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP)

**(74) Agent(s):**

TAKASHIMA, Hajime; Meiji Yasuda Seimei Osaka Midosuji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410044 (JP)

**(54) Title (EN):** FUSED HETEROCYCLIC RING COMPOUND

**(54) Title (FR):** COMPOSÉ À NOYAU HÉTÉROCYCLIQUE FUSIONNÉ

**(54) Title (JA):** 縮合複素環化合物

**(57) Abstract:**

**(EN):** Disclosed is a compound represented by formula (I) or a salt thereof, which has GPR 119 agonist action and excellent medicinal effects useful for prevention/treatment of diabetes, adiposis and the like. In the formula, P represents a substituted 6-membered aromatic ring; Q represents a (substituted) 6-membered aromatic ring; A<sup>1</sup> represents CR<sup>4a</sup>R<sup>4b</sup>, NR<sup>4c</sup>, O, S, SO, SO<sub>2</sub>

(wherein  $R^{4a}$ - $R^{4c}$  each represents H or the like);  $L^1$  represents a (substituted)  $C_{1-5}$  alkylene;  $L^2$  represents a bond, a (substituted)  $C_{1-3}$  alkylene;  $L^3$  and  $L^4$  each represents a (substituted)  $C_{1-3}$  alkylene;  $R^1$  represents H, X, CN, a (substituted) hydrocarbon, a (substituted) heterocyclic ring or a (substituted) OH, or alternatively combines with  $A^1$  to form a (substituted) 4- to 8-membered (heterocyclic) ring;  $R^2$  represents H, CN or a (substituted) hydrocarbon; and  $R^{3a}$  represents  $-\text{COSR}^{A1}$  or a (substituted) 5- or 6-membered aromatic ring (wherein  $R^{A1}$  represents a (substituted) hydrocarbon or a (substituted) heterocyclic ring.)

**(FR):** L'invention concerne un composé représenté par la formule (I) ou un sel de ce composé, qui présente une action d'antagoniste GPR119 et des effets médicaux excellents utiles à la prévention/au traitement des diabètes, de l'adipose et des maladies similaires. Dans la formule, P représente un noyau aromatique substitué à 6 chaînons; Q représente un noyau aromatique (substitué) à 6 chaînons;  $A^1$  représente un groupe  $\text{CR}^{4a}\text{R}^{4b}$ ,  $\text{NR}^{4c}$ , O, S, SO ou  $\text{SO}_2$  (où  $R^{4a}$  à  $R^{4c}$  représentent chacun un atome H ou un élément similaire);  $L^1$  représente un groupe alkylène en C1 à C5 (substitué);  $L^2$  représente un liaison, un groupe alkylène en C1 à C3 (substitué);  $L^3$  et  $L^4$  représentent chacun un groupe alkylène en C1 à C3 (substitué);  $R^1$  représente un atome H, X, un groupe CN, un hydrocarbure (substitué), un noyau hétérocyclique (substitué) ou un groupe OH (substitué), ou se combine sinon à  $A^1$  pour former un noyau (hétérocyclique) (substitué) à 4 à 8 chaînons;  $R^2$  représente un atome H, un groupe CN ou un hydrocarbure (substitué); et  $R^{3a}$  représente  $-\text{COSR}^{A1}$  ou un noyau aromatique (substitué) à 5 ou 6 chaînons (où  $R^{A1}$  représente un hydrocarbure (substitué) ou un noyau hétérocyclique (substitué)).

**(JA):** GPR119アゴニスト作用を有し、糖尿病、肥満症等の予防・治療に有用であり、かつ優れた薬効を有する、下記式(1)で表される化合物またはその塩。P:置換6員芳香環、Q:(置換)6員芳香環  
 $A^1$ : $\text{CR}^{4a}\text{R}^{4b}$ , $\text{NR}^{4c}$ ,O,S,SO, $\text{SO}_2$ { $R^{4a-4c}$ :H等}  $L^1$ :(置換) $C_{1-5}$ アルキル、 $L^2$ :結合,(置換) $C_{1-3}$ アルキル、 $L^{3-4}$ :(置換) $C_{1-3}$ アルキル、 $R^1$ :H,X,CN,(置換)炭化水素,(置換)複素環,(置換)OH又は $A^1$ と共に(置換)4-8員(複素)環、 $R^2$ :H,CN,(置換)炭化水素、 $R^{3a}$ : $-\text{COSR}^{A1}$ ,(置換)5-6員芳香環{ $R^{A1}$ :(置換)炭化水素,(置換)複素環}

#### International search report:

Received at International Bureau: 18 March 2010 (18.03.2010) [JP]

#### International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

#### (81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM